Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)

NCT06981637 PHASE2 RECRUITING

Maintenance Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Controlled Disease After Standard Anthracycline-based Treatment (MELODY)

Details

Lead sponsor	National Health Research Institutes, Taiwan
Phase	PHASE2
Status	RECRUITING
Enrolment	81
Start date	Wed Dec 31 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Jul 31 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Advanced Soft Tissue Sarcoma

Interventions

• Pegylated liposomal doxorubicin

Countries

Taiwan